Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT06050694
Phase
PHASE2
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • glofitamab
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Toronto, Ontario, Canada|43.70643,-79.39864
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Men and women ≥ 18 years of age deemed eligible for treatment with full-dose Pola- R-CHP and possible treatment with glofitamab by the qualified in…
  • Histologic diagnosis of DLBCL and variants according to the WHO 201613 or WHO 202254 classification including DLBCL non-organ-specific (NOS), Germi…
  • Previously untreated DLBCL with the following exceptions: (a) prior radiotherapy for palliation (not localized), (b) up to 7 days of corticosteroid…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →